110 related articles for article (PubMed ID: 7852772)
1. [Rectosigmoidectomy following neoadjuvant chemotherapy for advanced ovarian cancer].
Kato T; Shimizu Y; Umezawa S; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Dec; 46(12):1337-42. PubMed ID: 7852772
[TBL] [Abstract][Full Text] [Related]
2. [Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].
Shimizu Y; Tatsuki Y; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Dec; 44(12):1551-8. PubMed ID: 1484219
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for advanced ovarian cancer.
Schwartz PE; Chambers JT; Makuch R
Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of advanced ovarian cancer--is residual tumor diameter less than 2cm optimal?].
Shimizu Y; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Oct; 45(10):1129-35. PubMed ID: 8245592
[TBL] [Abstract][Full Text] [Related]
5. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
6. Surgical indications for combined partial rectosigmoidectomy in ovarian cancer.
Takahashi O; Sato N; Miura Y; Ogawa M; Fujimoto T; Tanaka H; Sato H; Tanaka T
J Obstet Gynaecol Res; 2005 Dec; 31(6):556-61. PubMed ID: 16343259
[TBL] [Abstract][Full Text] [Related]
7. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
Li M; Huang X
Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
9. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
10. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological characteristics of hereditary ovarian cancer syndrome].
Zhong Y; Sheng XG; Ma ZF; Ma YB; Liu NF; Chen YT; Gao R; Wang YY; Sun L
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):676-80. PubMed ID: 20079180
[TBL] [Abstract][Full Text] [Related]
13. [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
Kobayashi K; Fujimoto S; Takahashi M; Mutou T; Toyosawa T; Ohtsuka Y; Ogasawara T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1726-8. PubMed ID: 14619504
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer.
Lawton FG; Redman CW; Luesley DM; Chan KK; Blackledge G
Obstet Gynecol; 1989 Jan; 73(1):61-5. PubMed ID: 2462202
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy].
Ivanov S; Ivanov S; Khadzhiolov N
Akush Ginekol (Sofiia); 2004; 43(6):17-9. PubMed ID: 15669647
[TBL] [Abstract][Full Text] [Related]
16. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
17. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
18. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
[TBL] [Abstract][Full Text] [Related]
19. [Prognosis and prognostic factor analysis epithelial ovarian cancer].
Wen H; Sun W; Guo Y
Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):159-62. PubMed ID: 9596891
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
